BioSig Technologies to Participate in LD Micro’s Zooming with LD
July 23 2020 - 8:30AM
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, announced today that the Company would be
presenting at LD Micro’s Zooming with LD on Monday, July 27, 2020.
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc. will be presenting an overview of the Company as well as
recent developments and key highlights, including progress with
PURE EP(tm) system installations, the implementation of a
stockholders rights plan, BioSig’s subsidiary ViralClear
Pharmaceuticals, Inc.’s (ViralClear) creation of a Scientific
Advisory Board and enrollment of its Phase II clinical study of
merimepodib in combination with remdesivir in adult patients with
advanced COVID-19.
“With our stock up 34% year-to-date and the strongest balance
sheet in the Company’s history, we are well-positioned for
continuous value creation on behalf of our shareholders. Despite
the challenging environment, we remained steadfast in securing
hospital support for the PURE EP(tm) System’s ongoing and future
installations. Our pharmaceutical subsidiary ViralClear sees a
steady patient enrollment across many hospital sites. We are
pleased to reconnect with the LD Micro investor community and look
forward to reporting on our progress,” commented Kenneth L.
Londoner, Chairman and CEO of BioSig Technologies, Inc.
The BioSig presentation will take place virtually over Zoom on
Monday, July 27th. Mr. Londoner will also be available for
one-on-one meetings with investors on the same day. To
register for this 8 am PST presentation, click here.
About LD Micro LD Micro was founded in 2006
with the sole purpose of being an independent resource in the
microcap space. What started out as a newsletter highlighting
unique companies has transformed into several influential events
annually (Invitational, Summit, and Main Event). In 2015, LD Micro
launched ldmicro.com as a portal to provide
exclusive intraday information on the entire sector,
including the first pure micro-cap index (LDMi) which covers
stocks in North America with market capitalizations between
$50 million to $300 million. About BioSig
Technologies BioSig Technologies is a medical technology
company commercializing a proprietary biomedical signal processing
platform designed to improve signal fidelity and uncover the full
range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About ViralClear Pharmaceuticals, Inc. and Merimepodib
(MMPD)BioSig Technologies, Inc.’s (BSGM) subsidiary,
ViralClear Pharmaceuticals, Inc., is seeking to develop a novel
pharmaceutical called merimepodib to treat patients with COVID-19.
Merimepodib is intended to be orally administered, and has
demonstrated broad-spectrum in vitro antiviral activity, including
strong activity against SARS-CoV-2 in cell cultures. Merimepodib
was previously in development as a treatment for chronic hepatitis
C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex),
with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over
400 subjects and patients and an extensive preclinical safety
package was completed. A manuscript titled, “The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro”, was submitted to an online peer-reviewed life sciences
journal. This manuscript is authored by Natalya Bukreyeva, Rachel
A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and
Slobodan Paessler of the UTMB Galveston National Laboratory and Dr.
Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as
a corresponding author. This article highlights pre-clinical data
generated under contract with Galveston National Laboratory at The
University of Texas Medical Branch.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024